Product
Influenza Vaccine
Aliases
Influenza Vaccine, inactivated, quadrivlent(QIV), Influenza Vaccine, Live, Nasal, Freeze-dried, Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
12 clinical trials
9 indications
Indication
Multiple SclerosisIndication
Relapsing-RemittingIndication
COVID-19Indication
InfluenzaIndication
MumpsIndication
Seasonal InfluenzaIndication
HumanIndication
GCPIndication
GonorrheaClinical trial
A Phase IIIB, Multicenter, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Patients With Relapsing Forms of Multiple SclerosisStatus: Completed, Estimated PCD: 2017-02-14
Clinical trial
A Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1083 (SARS-Cov-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of AgeStatus: Active (not recruiting), Estimated PCD: 2024-05-21
Clinical trial
Multi-center, Randomized, Double-blind, Placebo-controlled Trial of a Live Attenuated Influenza Vaccine in People Aged 3-17Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and OlderStatus: Completed, Estimated PCD: 2022-06-17
Clinical trial
The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine Administrated Alone and Concomitantly With a Quadrivalent Inactivated Influenza Vaccine in Junior High School StudentsStatus: Active (not recruiting), Estimated PCD: 2024-02-02
Clinical trial
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID-19 AND INFLUENZA IN HEALTHY INDIVIDUALSStatus: Recruiting, Estimated PCD: 2024-12-05
Clinical trial
A Phase 2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle and Quadrivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix-M™ Adjuvant in Healthy Participants ≥ 50 to ≤ 80 Years of AgeStatus: Active (not recruiting), Estimated PCD: 2023-07-25
Clinical trial
A Phase Ⅲ, Randomized, Double-blind and Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Individuals Aged 3 Years and OlderStatus: Recruiting, Estimated PCD: 2023-09-30
Clinical trial
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of AgeStatus: Terminated, Estimated PCD: 2019-04-26
Clinical trial
The Shandong Provincial Center for Disease Control and Prevention, ChinaStatus: Completed, Estimated PCD: 2023-02-06
Clinical trial
Longitudinal Analysis of Bone Marrow and Peripheral Blood Immune Responses to Influenza Vaccination in a Healthy Adult CohortStatus: Recruiting, Estimated PCD: 2029-12-01
Clinical trial
Division of Microbiology and Infectious Diseases, (DMID) 21-0018: Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria GonorrhoeaeStatus: Recruiting, Estimated PCD: 2028-02-01